HILLEVAX INC (HLVX) Fundamental Analysis & Valuation

NASDAQ:HLVX • US43157M1027

Current stock price

2.09 USD
-0.01 (-0.48%)
At close:
2.1 USD
+0.01 (+0.48%)
After Hours:

This HLVX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. HLVX Profitability Analysis

1.1 Basic Checks

  • HLVX had negative earnings in the past year.
  • In the past year HLVX has reported a negative cash flow from operations.
  • In the past 5 years HLVX always reported negative net income.
  • HLVX had a negative operating cash flow in each of the past 5 years.
HLVX Yearly Net Income VS EBIT VS OCF VS FCFHLVX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

  • With a Return On Assets value of -40.65%, HLVX perfoms like the industry average, outperforming 58.70% of the companies in the same industry.
  • The Return On Equity of HLVX (-48.10%) is better than 66.48% of its industry peers.
Industry RankSector Rank
ROA -40.65%
ROE -48.1%
ROIC N/A
ROA(3y)-54.23%
ROA(5y)-132.64%
ROE(3y)-67.22%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
HLVX Yearly ROA, ROE, ROICHLVX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -200 -400

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for HLVX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
HLVX Yearly Profit, Operating, Gross MarginsHLVX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

7

2. HLVX Health Analysis

2.1 Basic Checks

  • Compared to 1 year ago, HLVX has more shares outstanding
  • HLVX has more shares outstanding than it did 5 years ago.
  • HLVX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
HLVX Yearly Shares OutstandingHLVX Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
HLVX Yearly Total Debt VS Total AssetsHLVX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

  • Based on the Altman-Z score of -1.98, we must say that HLVX is in the distress zone and has some risk of bankruptcy.
  • HLVX's Altman-Z score of -1.98 is in line compared to the rest of the industry. HLVX outperforms 52.22% of its industry peers.
  • There is no outstanding debt for HLVX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -1.98
ROIC/WACCN/A
WACCN/A
HLVX Yearly LT Debt VS Equity VS FCFHLVX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

  • HLVX has a Current Ratio of 26.39. This indicates that HLVX is financially healthy and has no problem in meeting its short term obligations.
  • HLVX has a Current ratio of 26.39. This is amongst the best in the industry. HLVX outperforms 97.41% of its industry peers.
  • HLVX has a Quick Ratio of 26.39. This indicates that HLVX is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of HLVX (26.39) is better than 97.41% of its industry peers.
Industry RankSector Rank
Current Ratio 26.39
Quick Ratio 26.39
HLVX Yearly Current Assets VS Current LiabilitesHLVX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 100M 200M 300M

1

3. HLVX Growth Analysis

3.1 Past

  • HLVX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 57.82%, which is quite impressive.
EPS 1Y (TTM)57.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%86.75%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, HLVX will show a quite strong growth in Earnings Per Share. The EPS will grow by 10.16% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y83.34%
EPS Next 2Y35.78%
EPS Next 3Y22.84%
EPS Next 5Y10.16%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
HLVX Yearly Revenue VS EstimatesHLVX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2031 2032 20M 40M 60M
HLVX Yearly EPS VS EstimatesHLVX Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -5 -10

1

4. HLVX Valuation Analysis

4.1 Price/Earnings Ratio

  • HLVX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year HLVX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
HLVX Price Earnings VS Forward Price EarningsHLVX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
HLVX Per share dataHLVX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

  • HLVX's earnings are expected to grow with 22.84% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.78%
EPS Next 3Y22.84%

0

5. HLVX Dividend Analysis

5.1 Amount

  • No dividends for HLVX!.
Industry RankSector Rank
Dividend Yield N/A

HLVX Fundamentals: All Metrics, Ratios and Statistics

HILLEVAX INC

NASDAQ:HLVX (9/16/2025, 8:00:01 PM)

After market: 2.1 +0.01 (+0.48%)

2.09

-0.01 (-0.48%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-06
Earnings (Next)N/A
Inst Owners47.55%
Inst Owner Change-100%
Ins Owners1.98%
Ins Owner Change0%
Market Cap104.79M
Revenue(TTM)N/A
Net Income(TTM)-71.10M
Analysts43.33
Price Target2.04 (-2.39%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)45.37%
Min EPS beat(2)22.97%
Max EPS beat(2)67.77%
EPS beat(4)2
Avg EPS beat(4)-8.83%
Min EPS beat(4)-104.08%
Max EPS beat(4)67.77%
EPS beat(8)4
Avg EPS beat(8)-4.94%
EPS beat(12)8
Avg EPS beat(12)10.04%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)11.11%
EPS NY rev (1m)0%
EPS NY rev (3m)15.52%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.71
P/tB 0.71
EV/EBITDA N/A
EPS(TTM)-1.43
EYN/A
EPS(NY)-0.47
Fwd EYN/A
FCF(TTM)-1.19
FCFYN/A
OCF(TTM)-1.18
OCFYN/A
SpS0
BVpS2.95
TBVpS2.95
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -40.65%
ROE -48.1%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-54.23%
ROA(5y)-132.64%
ROE(3y)-67.22%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score7
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 12.08%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 26.39
Quick Ratio 26.39
Altman-Z -1.98
F-Score7
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)57.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%86.75%
EPS Next Y83.34%
EPS Next 2Y35.78%
EPS Next 3Y22.84%
EPS Next 5Y10.16%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y63.64%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year14.22%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y32.45%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y22.42%
OCF growth 3YN/A
OCF growth 5YN/A

HILLEVAX INC / HLVX Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for HILLEVAX INC?

ChartMill assigns a fundamental rating of 3 / 10 to HLVX.


Can you provide the valuation status for HILLEVAX INC?

ChartMill assigns a valuation rating of 1 / 10 to HILLEVAX INC (HLVX). This can be considered as Overvalued.


How profitable is HILLEVAX INC (HLVX) stock?

HILLEVAX INC (HLVX) has a profitability rating of 1 / 10.


Can you provide the financial health for HLVX stock?

The financial health rating of HILLEVAX INC (HLVX) is 7 / 10.


Can you provide the expected EPS growth for HLVX stock?

The Earnings per Share (EPS) of HILLEVAX INC (HLVX) is expected to grow by 83.34% in the next year.